Midazolam 5mg Syrup + Vapendavir 264 mg BID + Vapendavir 528 mg QD
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug-Drug Interaction Healthy Volunteers
Conditions
Drug-Drug Interaction Healthy Volunteers
Trial Timeline
May 1, 2014 → Jun 1, 2014
NCT ID
NCT02204501About Midazolam 5mg Syrup + Vapendavir 264 mg BID + Vapendavir 528 mg QD
Midazolam 5mg Syrup + Vapendavir 264 mg BID + Vapendavir 528 mg QD is a phase 1 stage product being developed by Vaxart for Drug-Drug Interaction Healthy Volunteers. The current trial status is completed. This product is registered under clinical trial identifier NCT02204501. Target conditions include Drug-Drug Interaction Healthy Volunteers.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02204501 | Phase 1 | Completed |
Competing Products
15 competing products in Drug-Drug Interaction Healthy Volunteers